This company has been acquired
GreenLight Biosciences Holdings Resultados de beneficios anteriores
Pasado controles de criterios 0/6
GreenLight Biosciences Holdings's earnings have been declining at an average annual rate of -41.7%, while the Biotechs industry saw earnings growing at 32.1% annually. Revenues have been growing at an average rate of 577.3% per year.
Información clave
-41.7%
Tasa de crecimiento de los beneficios
93.2%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.0% |
| Tasa de crecimiento de los ingresos | 577.3% |
| Rentabilidad financiera | -717.2% |
| Margen neto | -1,521.0% |
| Última actualización de beneficios | 31 Mar 2023 |
Actualizaciones de resultados anteriores recientes
Recent updates
GreenLight Biosciences cutting 25% of staff as part of realignment
Oct 12GreenLight Biosciences launches $109M in financing
Aug 12GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccine
Aug 01GreenLight Biosciences: Synthesizing Cell-Free RNA
Apr 05Desglose de ingresos y gastos
Cómo gana y gasta dinero GreenLight Biosciences Holdings. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 23 | 10 | -157 | 35 | 0 |
| 31 Dec 22 | 7 | -167 | 36 | 0 |
| 30 Sep 22 | 4 | -163 | 34 | 0 |
| 30 Jun 22 | 3 | -154 | 31 | 0 |
| 31 Mar 22 | 2 | -129 | 26 | 0 |
| 31 Dec 21 | 2 | -112 | 20 | 0 |
| 30 Sep 21 | 1 | -86 | 17 | 0 |
| 30 Jun 21 | 2 | -89 | 15 | 0 |
| 31 Mar 21 | 2 | -75 | 13 | 0 |
| 31 Dec 20 | 2 | -53 | 11 | 0 |
| 31 Dec 19 | 3 | -37 | 9 | 0 |
Ingresos de calidad: GRNA is currently unprofitable.
Margen de beneficios creciente: GRNA is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: GRNA is unprofitable, and losses have increased over the past 5 years at a rate of 41.7% per year.
Acelerando crecimiento: Unable to compare GRNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: GRNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-43.2%).
Rentabilidad financiera
Alta ROE: GRNA has a negative Return on Equity (-717.16%), as it is currently unprofitable.